Therapy Areas: Oncology
Verastem Oncology presents two-year follow-up data on avutometinib and defactinib in recurrent low-grade serous ovarian cancer
10 April 2026 - Biopharmaceutical company Verastem Oncology (Nasdaq:VSTM) on Friday announced two-year median follow-up results from the Phase 2 RAMP 201 clinical trial of Avmapki Fakzynja combination...
DualityBio reports China NMPA acceptance of BLA for T-Pam for treatment of unresectable or metastatic HER2-positive breast cancer
10 April 2026 - Chinese biopharmaceutical company DualityBio (HK:9606) announced on Thursday that the Biologics License Application (BLA) for the investigational antibody-drug conjugate (ADC) trastuzu...
Oricell Therapeutics completes USD110m pre-IPO financing
10 April 2026 - Oricell Therapeutics Holdings Limited, a clinical-stage biotechnology company developing next-generation cell therapies for oncology and immunology, announced on Thursday the cumulativ...
Tempus expands oncology collaboration with Gilead to accelerate AI-driven R&D
9 April 2026 - Technology company Tempus AI Inc (NASDAQ:TEM) on Thursday announced an expanded multi-year collaboration with biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) to support the ...
Coiled Therapeutics reports enhanced efficacy for AO-252 and accelerates transition to dose expansion
8 April 2026 - Oncology company Coiled Therapeutics plc (AIM: COIL) reported on Monday that it has recorded improved clinical outcomes from its ongoing Phase I/II trial (NCT06136884) of AO-252, suppor...
IDEOlogy Health and West Cancer Center partner to advance patient-centred oncology education and care
8 April 2026 - IDEOlogy Health, a provider of non-promotional, multi-channel medical education to oncology professionals, on Tuesday announced two exclusive strategic partnership agreements with West ...